|Videos|May 24, 2021

Next-generation imaging and node-positive prostate cancer

Author(s)Urology Times staff

Jason Zhu, MD, a medical oncologist at Levine Cancer Institute, part of Atrium Health, discusses how next-generation imaging, such as PSMA-PET imaging, is critical to advancing personalized medicine in patients with lymph node–positive prostate cancer after prostatectomy.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC

ByHannah Clarke

July 22nd 2026

FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer

ByHannah Clarke

June 10th 2026

PRIMARY2 trial supports PSMA PET-CT in equivocal prostate MRI work-up

ByDeclan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol

March 23rd 2026

Laurence Klotz, MD, FRCSC, reveals the impact of micro-ultrasound on his prostate cancer practice

ByBenjamin P. Saylor, Strategic Content Lead,Hannah Clarke

March 18th 2026

EAU 2026: 64Cu-SAR-bisPSMA shows improved detection vs 68Ga-PSMA-11 in BCR of prostate cancer

ByHannah Clarke

March 17th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery